Clinical Trial Update: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a four-drug regimen (ombitasvir/paritaprevir/ritonavir + dasabuvir) with or without ribavirin for Hepatitis C in protease-inhibitor f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Dasabuvir (dasabuvir)
• Ombitasvir (ombitasvir)
• Paritaprevir (paritaprevir)
• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Hepatitis C | Phase 3 | Status: UNKNOWN